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Summary. Background: Direct acting oral anticoagulants (DOACs) are associated with less bleeding than traditional venous thromboembolism (VTE) treatments in the general population but are little studied in cancer-associated VTE (CA-VTE). Objective: To determine whether different anticoagulation strategies for CA-VTE have different hospitalized bleeding rates. Patients/Methods: We conducted a retrospective study of patients with CA-VTE, diagnosed between 2011 and 2015, in a large administrative database. Using validated algorithms, we identified 26 894 CA-VTE patients treated with anticoagulants and followed them for hospitalized severe bleeding. Cox models were used to assess bleeding risk, adjusted for age, sex, high dimensional propensity score and frailty. Results: Over 27 281 person-years of follow-up (median 0.6 years), 1204 bleeding events occurred, for a bleeding rate of 4.4% per patient-year. Bleeding rates varied by cancer type, with the highest rate for upper gastrointestinal cancers (8.6%) and the lowest for breast cancer (2.9%). In Cox models (hazard ratio [HR] ; 95% confidence interval [CI] ), compared with warfarin, DOACS and low-molecular-weight heparin (LMWH) had similar hazards of bleeding (HR, 0.88; 95% CI, 0.69-1.11 and 0.98; 0.85-1.13). Compared with LMWH, there was no difference in hazard of bleeding with DOACs (0.86; 0.66-1.12). There was heterogeneity in bleeding risk with DOACs by cancer type, with a higher risk of bleeding in upper gastrointestinal cancers and lower risk of bleeding in prostate cancer and hematologic cancers. Conclusions:
Introduction
One in five of the 900 000 annual venous thromboembolisms (VTEs) in the USA are associated with cancer [1, 2] . Although in the general population treatment of VTE with anticoagulation is highly effective and safe, patients with cancer-associated VTE (CA-VTE) experience a greater burden of anticoagulation failure and bleeding than other patients with traditional treatments for VTE [3, 4] . Thrombosis, including VTE, is the leading cause of death among cancer patients after the cancer itself [5] .
Before the introduction of the direct acting oral anticoagulants (DOAC) to treat VTE, options for outpatient anticoagulation treatment were limited to oral vitamin K antagonists (mainly warfarin in the USA) and subcutaneous heparin preparations (including low-molecularweight heparins [LMWHs] ) [4] . Vitamin K antagonists have many limitations in patients with cancer, including drug interactions and difficulty scaling the anticoagulant effect with rapidly changing bleeding risk factors. As such, heparin preparations, which lack these limitations, are the preferred treatment for CA-VTE. However, they are inconvenient as they require subcutaneous injections [6] .
Since 2012, a series of DOACs (apixaban [7] , dabigatran [8] , edoxaban [9] and rivaroxaban [10] ) have been approved to treat VTE [4] . The DOACs have reliable dosing in most individuals and are as effective as warfarin for treating VTE, with similar to reduced bleeding rates, making DOACs an attractive potential treatment option for cancer-associated VTE (CA-VTE) [11] . Unfortunately, given the relative novelty of DOACs and the small numbers of active cancer patients in clinical trials of DOACs to treat VTE, the best way to incorporate DOACs into the care of patients with CA-VTE is not established [12, 13] .
To address this knowledge gap, we used MarketScan, a commercial claims database, to assess the impact of anticoagulation choice on hospitalized bleeding risk during the treatment of CA-VTE. We hypothesized that warfarin would have the highest bleeding risk, with DOACs and LMWH having lower bleeding risks.
Methods

Study population/MarketScan database
The Truven Health MarketScan Commercial Claims and Encounters Database and the Medicare Supplemental and Coordination of Benefits Database (Truven Health Analytics Inc., Ann Arbor, MI, USA) provide a representative sample of~43.6 million Americans each year. We conducted a retrospective cohort study from 1 January 2011 through to 30 September 2015, with information collected via inpatient and outpatient claims, including medication and procedure claims. The initial sample included 429 246 patients aged 18-99 years with at least one inpatient or two outpatient claims for VTE 7 to 365 days apart and one outpatient anticoagulation prescription within 4 weeks of the VTE (International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes 415. 19, 451.19, 453.29, 453 .49, 453.59, 453.89 or 453.99 in any position). ICD-9-CM codes for identifying VTE have a positive predictive value (PPV) of approximately 85%, which increases to 91% when requiring treatment of VTE [14] [15] [16] [17] [18] [19] [20] . After restricting our sample to those with > 90 days of continuous enrollment prior to their anticoagulant prescription, and including only the first enrollment period in the event of a temporary disenrollment, there were 151 246 patients with VTE.
Among patients with VTE, we identified 32 513 patients with a cancer ICD-9-CM diagnosis claim in any position prior to their VTE diagnosis (Table S1 ). Patients were considered to have active cancer-directed therapy if they had at least one claim for any of the following before the diagnosis of VTE: (i) an inpatient ICD-9-CM chemotherapy encounter or J-code, (ii) a chemotherapy 'therapeutic class' or 'therapeutic group' drug code, (iii) a radiation therapy code, (iv) an inpatient chemotherapy or surgery MS-DRG code, or (v) an outpatient cancer surgery procedure code (Table S2 ) [21] . The final analytic sample included 26 894 patients being actively treated for cancer concurrent with or before anticoagulant initiation (Fig. 1) .
Anticoagulant use
Patient exposure was categorized, based on the first anticoagulant prescribed concurrent with or within 4 weeks after a VTE diagnosis (to mirror an intention to treat analysis), as a new warfarin user, a new LMWH user (enoxaparin, dalteparin, fondaparinux or heparin) or a new DOAC user (apixaban, dabigatran or rivaroxaban). To account for anticoagulation overlap while becoming therapeutic on warfarin, individuals whose first anticoagulant was LMWH but received a warfarin prescription within 16 days were classified as warfarin users. Individuals on an oral anticoagulant prior to their first VTE were excluded from further analysis. Although not LMWHs, heparin and fondaparinux were included in this category because of their similar clinical profiles. The validity of warfarin claims in administrative databases has a sensitivity of 94% and PPV of 99%; the validity for LMWH and DOACs claims is likely to be similar in the context of this study [22] . Comparisons of anticoagulants for this analysis included warfarin vs. DOACs, warfarin vs. LMWH, and LMWH vs. DOACs. Any comparisons with DOACs were restricted to after 2 November 2012, the FDA approval date for rivaroxaban.
Outcome ascertainment
The main outcome of the study was hospitalized bleeding events defined as intracranial bleeding or gastrointestinal (GI) bleeding, or other bleeding events identified from inpatient claims using validated algorithms [23] in those without a history of major bleeding (Table S3 ). This algorithm has a positive predictive value of 86% for identifying serious bleeding events and is comparable to other peer-reviewed algorithms [24, 25] .
Assessment of covariates
Covariates, including frailty, were defined based on inpatient, outpatient and pharmacy claims that occurred within 3 months prior to the index date using validated published algorithms (Tables S4 and S5 ) [23, [26] [27] [28] .
Statistical analysis
High dimensional propensity scores (HDPS) were calculated and included predefined variables of age, sex and calendar year [29, 30] . Empirical covariates were defined using five domains: inpatient diagnostic codes, outpatient diagnostic codes, inpatient procedure codes, outpatient procedure codes, and pharmacy claims excluding anticoagulants. Within each of the five domains, the top 200 most prevalent conditions were selected, resulting in 1000 candidate covariates. The variables were then ranked based on the ratio of prevalence of the candidate covariates in the exposed vs. the unexposed groups. The top 500 candidate covariates were then selected along with the predefined covariates to calculate propensity scores. Separate HDPS were calculated for each of the anticoagulant-outcome pairs (1 outcome 9 3 comparison groups = 3 total HDPS).
Cox proportional hazards models were used to estimate the association between anticoagulant choice and the time to severe bleeding event for the following comparisons: (i) new warfarin users to new DOAC users; (ii) new warfarin users to new LMWH users and (iii) new LMWH users to new DOAC users. Follow-up began at the date of anticoagulant initiation and continued until hospitalized bleeding, health plan disenrollment or the end of study follow-up, whichever occurred first. Four models were conducted for each comparison for all active cancer patients: (i) crude association; (ii) adjusted for age, sex and calendar year; (iii) adjusted for age, sex, calendar year and HDPS and (iv) adjusted for age, sex, calendar year, HDPS and frailty. Stratified analyses were conducted for specific cancer types, including lung, breast, prostate, colorectal, upper gastrointestinal (GI) and hematologic (leukemia, lymphoma and myeloma) cancers. Effect modification by sex, age (< 75, > 75 years) and kidney disease were explored using stratified analyses. Sensitivity analyses were carried out excluding individuals not receiving chemotherapy as part of their cancer treatment. All statistical analyses were performed with SAS v 9.4 (SAS Inc., Cary, NC, USA).
We conformed with all regulations from the Health Insurance Portability and Accountability Act and the Declaration of Helsinki. The protocol was reviewed by the University of Minnesota Institutional Review Board and determined to be exempt from review.
Results
There were 26 894 CA-VTE cases occurring between 2011 and 2015, of which 14.6% of patients had lung cancer, 14.5% had breast cancer, 13.2% had hematologic cancers, 9.6% had colon cancer, 9.5% had prostate cancer and 3.5% had upper gastrointestinal cancer (Table 1) . Of the CA-VTE, 14 833 were treated with warfarin (55.2%), 8803 with LMWH (32.7%) and 3258 with a DOAC (12.1%), of whom 2922 were treated with rivaroxaban (89.7% of DOAC usage). characteristics of the analytic sample by anticoagulant choice. In general, the population characteristics were similar for oral anticoagulants (DOACs and warfarin), although individuals treated with LMWH were younger and had a lower burden of chronic diseases. Lower percentages of breast and prostate cancer VTE cases were treated with LMWH. A total of 1204 bleeding events occurred over 27 281 person-years of follow-up (mean follow-up, 1.00 year; SD, 1.00 year; maximum 4.5 years). Table 2 presents the unadjusted number of bleeding events and bleeding rates by anticoagulant choice and cancer type. The overall bleeding rate was 4.4% per patient-year. Bleeding rates differed by cancer type; the unadjusted rate was highest in patients with upper gastrointestinal cancers (8.6% per patient-year), with lower rates in lung cancer (6.0% per patient-year), colorectal cancer (4.5% per patient-year), prostate cancer (4.0% per patient-year), hematologic cancer (3.5% per patient-year) and breast cancer (2.9% per patient-year).
We next assessed the association of initial choice of anticoagulant to treat CA-VTE with bleeding, both overall and by cancer type, using sequentially adjusted Cox proportional hazard models (Table 3 ). In multivariable-adjusted Cox models, which included all cancer types, users of DOACs had a similar hazard of bleeding compared with users of warfarin, with little indication of confounding after adjusting for age, sex, year, the HDPS or frailty. In the unadjusted Although there were borderline interactions between anticoagulant choice and age (stratified as less than 75 or greater than or equal to 75 years) and sex (but not kidney disease), the point estimates either crossed 1 or could be explained by different incidences of types of cancer in men vs. women (i.e. prostate and breast cancer, Table S6 ). When the population was restricted to those receiving chemotherapy as part of their cancer treatment (Table 3) , the association of DOACs with bleeding vs. warfarin was closer to 1 (HR, 0.95; 95% CI, 0.68-1.34), with a similar finding for DOACs vs. LMWH (HR, 1.05; 95% CI, 0.75-1.47).
Discussion
In this analysis of nearly 27 000 patients with anticoagulant-treated CA-VTE there were 1204 hospitalized bleeding events, resulting in an anticoagulation-associated bleeding rate of 4.4% per patient-year. DOACs were associated with a similar hazard of bleeding compared to warfarin (À12%; 95% CI, À11 to 31) and a similar hazard of bleeding compared to LMWH (À14%; 95% CI, À12 to 33). There were lower point estimates for the risks of bleeding for DOACs vs. warfarin in prostate and hematologic cancers, and a higher point estimate for bleeding for DOACs vs. warfarin for upper gastrointestinal cancers. Our findings are consistent with the current knowledge about warfarin vs. LMWH for the treatment of CA-VTE and extend knowledge about bleeding rates with the use of DOACs in CA-VTE, specifically demonstrating that DOACs are associated with similar bleeding risks to warfarin and LMWH, with potentially different bleeding risks by cancer site.
LMWH vs. warfarin
We observed no difference in bleeding risk with LMWH vs. warfarin for treatment of CA-VTE. Recommendations to use LMWH over vitamin K antagonists to treat CA-VTE [3, 31] are driven by reduced VTE recurrence, not a reduction in bleeding [32, 33] . The annual incidence rate of bleeding in the current study's LMWH-treated group (5.2%; 373 bleeds/8803 patients) was similar to the annual incidence rate of major bleeding in the LMWH group (4.0%; 21 bleeds/524 patients) reported in a recently published randomized trial of LMWH and edoxaban vs. LMWH alone to treat CA-VTE [34] . Notably, the rates or incidences of bleeding in patients treated for CA-VTE are variable in the literature. Trials have often reported higher incidences or rates [35] than observed in the present study, although with different definitions of bleeding, including outpatient bleeding events.
DOACs vs. warfarin and LMWH
Based on trials of DOACs vs. warfarin, DOACs are thought to have a similar or lower risk of bleeding compared with warfarin [11] . However, these trials were of general VTE patients and included very few VTE patients with cancer, let alone cancer being actively treated. Until recently the only data on bleeding risk among CA-VTE patients using DOACs has come from smaller observational studies [36] or pooled data from randomized controlled trials of VTE in more general populations stratifying by cancer patients [13, 35, 37, 38] . The number of bleeding events among DOAC-treated CA-VTE in these analyses was limited, with 41 major bleeds and 74 clinically relevant bleeding events among 600 patients [33, 35] . In our study, 115 hospitalized major bleeding events occurred among 3258 CA-VTE patients using DOACs. We demonstrated a marginally lower risk of bleeding with DOACs vs. warfarin (HR, 0.88; 95% CI, 0.69-1.11), consistent with two different meta-analyses [33, 39] , with poorer precision than the present analysis, which demonstrated the incidence of bleeding was similar between DOACS and warfarin for CA-VTE ( [39] , similar to our findings (HR, 0.86; 95% CI, 0.66-1.12). Confusing the issue, in a randomized controlled trial of LMWH bridge followed by edoxaban vs. LMWH alone to treat CA-VTE, the risk of major bleeding was higher in the edoxaban plus LMWH group vs. LMWH group (HR, 1.77; 95% CI, 1.03-3.04). However, precision was poor for that analysis as there were only 36 bleeding events in the edoxaban arm and 21 bleeding events in the LMWH arm among 1046 patients. The higher rate of major bleeding seen with edoxaban in this study could be a result of drug-specific effects of edoxaban vs. rivaroxaban (the most commonly used DOAC in our analyses), unappreciated differences in the patient populations, or chance. In a pilot study of 406 patients randomized to rivaroxaban vs. LMWH to treat CA-VTE, rivaroxaban did not have a higher risk of major bleeding than LMWH, but did have an increased risk of clinically relevant non-major bleeding [40] .
Thus, the current study demonstrated a similar bleeding risk for DOACs vs. LMWH, but a slightly reduced rate of major bleeding associated with DOACs vs. warfarin. These findings are consistent with smaller pooled analyses of patients with CA-VTE who participated in randomized clinical trials of DOACs vs. warfarin, which demonstrated an equivalent rate of major bleeding for DOACs vs. warfarin. However, our findings differ from one randomized controlled trial in CA-VTE patients, which demonstrated an increased risk of bleeding for edoxaban vs. LMWH.
DOACs and bleeding risk by cancer type
In the present analysis there was some evidence that DOACs were particularly beneficial in the context of VTE associated with prostate cancer and to a lesser extent in hematologic cancers, although precision was limited for the cancer-specific analyses. There is a strong [11] . Patients whose cancers impact their organ function more or who are treated more often with agents that reduce the metabolism of DOACs may be exposed to a greater anticoagulant effect of DOACs and suffer an increased risk of bleeding as a result. As the anticoagulant effect of DOACs is not readily measureable, unlike for warfarin or LMWH, these differences in anticoagulant exposure are likely to go unrealized [41] . In the data presented here, patients with prostate cancer had a strong trend for a lower risk of bleeding with DOACs vs. warfarin or LMWH. Patients with prostate cancer are often treated with local therapies alone (radiation or surgery) or androgen-deprivation therapy, which are not known to affect DOAC metabolism [42, 43] . Other cancer types, such as breast cancer or upper gastrointestinal cancers, are treated with agents that may interfere with DOAC metabolism and increase exposure to the anticoagulant effects of DOACs [43, 44] . Different impacts on bleeding risk by cancer type could explain why the current results differ from the two randomized controlled trials demonstrating increased bleeding risk with edoxaban and rivaroxaban vs. LMWH [34, 40] . These hypotheses are preliminary but highlight the need to assess risks and benefits of anticoagulants in diverse cancer patient populations.
Strengths and limitations
The use of administrative data represents both the greatest strength and the greatest limitation of our analyses. We have large numbers of people with CA-VTE in our analyses, but lose the data granularity of prospectively recruited patient populations as risk factors such as obesity are impossible to assess. Further, we could detect only the most severe bleeding events resulting in hospitalization and missed clinically relevant bleeding not resulting in hospitalization. Ideally, we would conduct a large randomized controlled trial comparing multiple agents, however, this is not feasible because the resources and time needed to prospectively enrol and follow 30 000 patients with CA-VTE would be immense. In order to minimize the weaknesses associated with administrative data, such as misclassification and confounding biases, 'best practice' pharmacoepidemiology approaches were utilized when analysing the data. First, we used well-validated definitions for administrative data for VTE and for bleeding. Although some misclassification was certainly present, both characteristics of our patient population and bleeding rates in the present analysis were consistent with prior studies, supporting the validity of our methods. In terms of defining OACs using administrative data, the validity of warfarin claims is excellent, and that of DOACs is likely to be similar [22] . However, patients often switch anticoagulants during the treatment of CA-VTE and those who switch may be different to those who do not, leading to bias [45] . To mitigate this, our analyses were based on OAC initially prescribed, following the intent-to-treat principle, which has been shown to be advantageous in making observational data more closely resemble clinical trial data [46] . Secondly, adjustment for high dimensional propensity scores and frailty was used to minimize confounding. We do, however, acknowledge that providers who do not follow guidelines for treatment of CA-VTE and use DOACs or warfarin may not follow other standard practices and outcomes for these patients may differ. A final issue is that, despite having nearly 30 000 CA-VTE patients who experienced over 1200 bleeding events in our analysis, we had poor precision for some analyses, such as comparisons of various DOACs with each other, and stratified analyses by cancer type, age, sex and organ function.
Conclusions
DOACs (mostly rivaroxaban) were associated with a similar incidence of bleeding vs. warfarin and LMWH in this population of CA-VTE patients. There was heterogeneity of the association by cancer type, especially for individuals with prostate cancer and upper GI malignancies. These data, in addition to other observational and randomized trial data, suggest that DOACs may be appropriate for treating some CA-VTEs and support clinical equipoise for further randomized clinical trials in appropriate populations. Future studies must address effects of individual DOACs on bleeding risk as well as the impact of cancer type on bleeding risk. Zakai and P. L. Lutsey were responsible for the concept and design. All authors were responsible for the interpretation of analyses and critical revision of manuscript.
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